Investigational Drug Information for BMS-986165

What is the development status for investigational drug BMS-986165?

BMS-986165 is an investigational drug.

There have been 52 clinical trials for BMS-986165. The most recent clinical trial was a Phase 3 trial, which was initiated on January 30^th 2023.

The most common disease conditions in clinical trials are Psoriasis, Lupus Erythematosus, Systemic, and Arthritis, Psoriatic. The leading clinical trial sponsors are Bristol-Myers Squibb, Covance, and Beth Israel Deaconess Medical Center.

There are two US patents protecting this investigational drug and sixty-four international patents.

Summary for BMS-986165

US Patents	2
International Patents	64
US Patent Applications	19
WIPO Patent Applications	10
Japanese Patent Applications	0
Clinical Trial Progress	Phase 3 (2023-01-30)
Vendors	36

Recent Clinical Trials for BMS-986165

Title	Sponsor	Phase
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).	Bristol-Myers Squibb	Phase 2
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).	Beth Israel Deaconess Medical Center	Phase 2
A Study of Deucravacitinib to Treat LPP and FFA	Bristol-Myers Squibb	Phase 2

See all BMS-986165 clinical trials

Clinical Trial Summary for BMS-986165

Top disease conditions for BMS-986165

Top clinical trial sponsors for BMS-986165

See all BMS-986165 clinical trials

US Patents for BMS-986165

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
BMS-986165
BMS-986165

International Patents for BMS-986165

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
BMS-986165	Argentina	AR094452	2032-11-08
BMS-986165	Australia	AU2013341186	2032-11-08
BMS-986165	Australia	AU2017201076	2032-11-08
BMS-986165	Australia	AU2018267545	2032-11-08
BMS-986165	Australia	AU2020203967	2032-11-08